The Novartis logo is visible on a group building in Rotkreuz
Novartis raised its medium-term sales forecasts on Thursday, forecasting annual growth of 6% until 2028, thanks to the strong momentum of the drugs launched and the prospect of future launches on the market.
The Swiss drugmaker previously targeted medium-term, currency-adjusted sales growth of at least 5% between 2023 and 2028.
The group added that during the period 2024-2029, it still expected growth of 5% per year, given its strong performance in 2024.
Novartis, which cut jobs and spun off generic drug company Sandoz to focus on developing new drugs, reaffirmed its goal of a base margin of at least 40% by 2027.
The group also revised upwards the estimate of maximum annual sales of five drugs with sales potential worth billions, namely Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio.
(Report by Ludwig Burger, French version by Elena Smirnova, edited by Augustin Turpin)
Business
